| 名稱(chēng) | CCDC6-RET V804M/BaF3激酶細(xì)胞 |
| 型號(hào) | CBP73216 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | CCDC6-RET V804M/BaF3激酶細(xì)胞 |
產(chǎn)品搜索
產(chǎn)品分類(lèi)
相關(guān)文章
- 細(xì)胞株的表達(dá)量越高越好嗎？
- 偏頭痛治療靶點(diǎn)——CGRP與藥篩細(xì)胞模型
- 4-1BB（CD137）靶點(diǎn)藥物篩選模型
- ATCC細(xì)胞株開(kāi)發(fā)的四階段簡(jiǎn)介
- PD-1/PD-L1:研發(fā)過(guò)剩還是大有可為
- PIM-1激酶抑制劑細(xì)胞篩選模型
- 有關(guān)腫瘤細(xì)胞的基因突變研究講解
- 從《指導(dǎo)原則》中分析參考品盤(pán)設(shè)計(jì)
- 分子診斷標(biāo)準(zhǔn)品，匠心出品，免費(fèi)申領(lǐng)
- GLP-1R、GCGR、GIPR多靶點(diǎn)激動(dòng)劑與代謝疾病
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73216CCDC6-RET V804M/BaF3激酶細(xì)胞
- 詳細(xì)內(nèi)容
CCDC6-RET V804M/BaF3激酶細(xì)胞
| CBP73216 | |
| I. Introduction | |
Cell Line Name： | CCDC6-RET [V804M]/BaF3 |
Host Cell: | BA/F3 |
| Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS+2ug/ml puromycin |
Mycoplasma Status: | Negative |
| II.Background | |
CCDC6, coiled-coil domain containing 6, has been shown to play a role in the DNA damaging signaling pathway acting as a substrate of ATM (PMID: 17420723). CCDC6 fusions with RET (PMID: 23154560, PMID: 26078337) and BRAF (PMID: 26314551) have been observed in multiple cancer types. | |
| III. Representative Data | |
1. CCDC6-RET V804M/BaF3
| |
2. Sanger of CCDC6-RET [V804M]/BaF3 | |
Figure 2. Breakpoint of CCDC6-RET V804M/BaF3 | |
Figure 3. Point mutation of CCDC6-RET V804M/BaF3 | |
| 3.Anti-proliferation assay | |
Figure 4. CTG Assay for CCDC6-Ret V804M BaF3 Proliferation. | |
會(huì)員_a.png)